Anti-ERCC1 [8F1]

The mammalian ERCC1 (Excision Repair Cross Complementing) polypeptide is required for nucleotide excision repair (NER) of damaged DNA and is homologous to Saccharomyces cerevisiae RAD10, which functions in repair and mitotic intrachromosomal recombination.

Contributors

Inventor Institute
Rick Wood Cancer Research UK, London Research Institute: Lincoln's Inn Fields
Cat. #: 153782
Tool sub type: Primary antibody
Unit size: 100 ug
Research Fields: Cancer;Genetics
Application: FACS ; IHC ; IF ; IP ; WB
Target: ERCC1
Reactivity: Human ; Rat
Host: Mouse
Class: Monoclonal
Alternate name: ERCC Excision Repair 1, Endonuclease Non-Catalytic Subunit, Excision Repair Cross-Complementing Rodent Repair Deficiency, Complementation Group 1 (Includes Overlapping Antisense Sequence), Excision Repair Cross-Complementation Group 1, DNA Excision Repair Protein ERCC-1, COFS4, RAD1, UV2
Product description: The mammalian ERCC1 (Excision Repair Cross Complementing) polypeptide is required for nucleotide excision repair (NER) of damaged DNA and is homologous to Saccharomyces cerevisiae RAD10, which functions in repair and mitotic intrachromosomal recombination. NER mechanism involves dual incisions on both sides of the damage catalyzed by two nucleases. In mammalian cells XPG cleaves 3' of the DNA lesion while the ERCC1-XPF complex makes the 5' incision. Elevated levels of ERCC1 have been reported in Cisplatin-resistant cells. Defects in ERCC1 are the cause of cerebro-oculo-facio-skeletal syndrome type 4 (COFS4) [MIM:610758]. COFS is a degenerative autosomal recessive disorder of prenatal onset affecting the brain, eye and spinal cord. After birth, it leads to brain atrophy, hypoplasia of the corpus callosum, hypotonia, cataracts, microcornea, optic atrophy, progressive joint contractures and growth failure. Facial dysmorphism is a constant feature. Abnormalities of the skull, eyes, limbs, heart and kidney also occur.
Conjugation: Unconjugated
Isotype: IgG2b
Molecular weight: 36 kDa
Immunogen: Full length, HIS-tagged recombinant Human ERCC1
Target background: The mammalian ERCC1 (Excision Repair Cross Complementing) polypeptide is required for nucleotide excision repair (NER) of damaged DNA and is homologous to Saccharomyces cerevisiae RAD10, which functions in repair and mitotic intrachromosomal recombination. NER mechanism involves dual incisions on both sides of the damage catalyzed by two nucleases. In mammalian cells XPG cleaves 3' of the DNA lesion while the ERCC1-XPF complex makes the 5' incision. Elevated levels of ERCC1 have been reported in Cisplatin-resistant cells. Defects in ERCC1 are the cause of cerebro-oculo-facio-skeletal syndrome type 4 (COFS4) [MIM:610758]. COFS is a degenerative autosomal recessive disorder of prenatal onset affecting the brain, eye and spinal cord. After birth, it leads to brain atrophy, hypoplasia of the corpus callosum, hypotonia, cataracts, microcornea, optic atrophy, progressive joint contractures and growth failure. Facial dysmorphism is a constant feature. Abnormalities of the skull, eyes, limbs, heart and kidney also occur.
Format: Liquid
Concentration: 0.9-1.1 mg/ml
Storage buffer: PBS with 0.02% azide
Storage conditions: -20° C
Shipping conditions: Dry ice
References:

Kuhlmann et al. 2014. Clin Chem. 60(10):1282-9. PMID: 25015375.

ERCC1-positive circulating tumor cells in the blood of ovarian cancer patients as a predictive biomarker for platinum resistance.

Wilcox et al. 2006. N Engl J Med. 355(24):2590

author reply 2591. PMID: 17171818.

DNA repair by ERCC1 in non-small-cell lung cancer.

Reed et al. 2006. N Engl J Med. 355(10):1054-5. PMID: 16957152.

ERCC1 measurements in clinical oncology.

Wachters et al. 2005. Lung Cancer. 50(2):211-9. PMID: 16169122.

ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy.

Images

View Gallery

Related Tools for Antibodies

Cat. # Tool Name
151016 Anti-CyclinA [E72.1] Key Info View Tool
151029 Anti-HSVICP8 [11E2] Key Info View Tool
151033 Anti-HSVUL42 [13C9] Key Info View Tool
151037 Anti-Cdk1 [17 (A17)] Key Info View Tool
151026 Anti-FCGR1 [10.1] mAb Key Info View Tool

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.